Other News To Note
Monday, December 3, 2012
Exelixis Inc., of South San Francisco, said the European Medicines Agency accepted for review the marketing authorization application for Cometriq (cabozantinib) for the proposed indication of progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.